C Michael Gibson/Baim Institute
Feb 16, 2026, 06:21
C. Michael Gibson: Favorable Safety Outcomes With Asundexian
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, and Executive Board Member at EXCITE International, shared a post on LinkedIn:
”No increase in any type of bleeding with Asundexian. Even minor bleeding was not increased (was numerically lower).”
Stay updated with Hemostasis Today.
-
Feb 16, 2026, 06:18Jecko Thachil: What Do Clinicians Mean by “Coagulopathy”?
-
Feb 16, 2026, 06:04Inside 2026 Highlights of ASH in the Mediterranean, Middle East, and North Africa with Dr. Heghine Khachatryan
-
Feb 15, 2026, 10:56Don’t Miss PNH: Clinical Practice From ISTH – Medscape
-
Feb 15, 2026, 10:52Awareness and Research on Factor V Deficiency Are Critical – EHC
-
Feb 15, 2026, 10:43Peter Zdziarski: Protecting Patient Data in the Rare Disease Community
-
Feb 15, 2026, 10:31Michiel Voet: The Price Tag of a Whole Blood Strategy
-
Feb 15, 2026, 10:26Sifat Jubaira: K₂-EDTA vs K₃-EDTA – Same Anticoagulant, Very Different Accuracy
-
Feb 15, 2026, 09:29Gevorg Tamamyan: Childhood Cancer is Curable. Inequity Is Not
-
Feb 15, 2026, 07:24Ekaterina Balaian Extends Sincere Gratitude to The Team at The Yeolyan Hematology and Oncology Center